FATE – Fate Therapeutics Inc

Fate Therapeutics, Inc. 于2007年4月27日在特拉华州合并,是一家临床分期生物制药公司,致力于成体干细胞治疗调节器的探索与开发,治疗罕见疾病,包括一些恶性血液病、溶酶体贮积症和肌肉营养不良。Fate使用的一些新方法采用已有的治疗模式,包括小分子和治疗性蛋白,并瞄准良好的生物机制,以增强成体干细胞的疗效。

中文介绍: https://xueqiu.com/S/FATE

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company’s cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

英文介绍: https://www.morningstar.com/stocks/xnas/fate/quote

主题测试文章,只做测试使用。发布者:star,转转请注明出处:http://wallstreetgm.com/fate-fate-therapeutics-inc/

发表评论

邮箱地址不会被公开。 必填项已用*标注